Sorry, you need to enable JavaScript to visit this website.

For APPs & Nurses | DARZALEX® (daratumumab) & DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)
efficacy & safety

~5 years of efficacy & safety data for DARZALEX® + Rd in newly diagnosed, transplant-ineligible patients1,2


The science behind DARZALEX FASPRO® and DARZALEX®


Administering DARZALEX FASPRO®

Resources for your practice to help your patients

Tap into education and guidance to support you and your patients along the treatment journey

Patient brochure

Educates patients on multiple myeloma and treatment with DARZALEX FASPRO®

Dosing calendar

Helps patients stay on track with their DARZALEX FASPRO® treatment regimen

DARZALEX FASPRO® doctor conversation guide

Assists patients with preparing questions for their doctor about DARZALEX FASPRO®

DARZALEX® personalized doctor conversation starter

Allows patients to choose questions about DARZALEX® to discuss with their doctor

Patient education and support program

Provides one-on-one guidance, information, and education to help patients start and stay on treatment

Patient support organizations

Provide education, resources, and research for patients with multiple myeloma


Explains the science behind daratumumab and hyaluronidase, the active ingredients in DARZALEX FASPRO®


Explains how daratumumab, the active ingredient in DARZALEX®, works in the body

Dosing and administration guide

Provides step-by-step instructions on how to administer DARZALEX FASPRO® and DARZALEX®

Dosing and administration video

Demonstrates how to administer an injection of DARZALEX FASPRO®

DRd=DARZALEX® (D) + lenalidomide (R) + dexamethasone (d); MOA=mechanism of action; Rd=lenalidomide (R) + dexamethasone (d).